Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: written description
Novartis v. Accord Redux – Panel 2 Reverses Panel 1
To save me a lot of typing, please read my post of January 10, 2022, summarizing the first Panel’s holding in Novartis Pharmaceutical v Accord Healthcare, Inc., 21 F.4th 1362 (Fed. Cir., 2022). The panel in that decision was Judges … Continue reading
The Unacknowledged Role of Section 112 in the Myriad Decisions
Guest post from Paul Cole, Lucas & Co., UK; introduction by Warren Woessner. In this interesting note, Paul Cole explores the possible effect on the Fed. Cir. and Supreme Court’s decisions about the patent-eligibility of “genomic DNA” of the arguable … Continue reading
Posted in Patent Eligible Subject Matter
Tagged application to bacterial genes, biotechnology, biotechnology law, blanket prohibition, BRCA1, cDNA, chemist or geneticist, Enablement, evaluation, full-length gene partial sequence, intellectual property, ip, Myriad, Patent Law, patent-eligibility, patents, Paul Cole, structural difference threshold, utility threshold, Warren Woessner, written description
Leave a comment